Sumatriptan and naratriptan tolerability and safety: an update of post-marketing experience.
Welch
K M
KM
University of Kansas School of Medicine, 3901 Rainbow Boulevard, Room 3022 Murphy, Kansas City, KS 66160-7300, USA.
D000075202:Contraindications; D003326:Coronary Circulation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects*; D007279:Injections, Subcutaneous; D008881:Migraine Disorders / Q000188:drug therapy*; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects*; D011358:Product Surveillance, Postmarketing; D012307:Risk Factors; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D018170:Sumatriptan / Q000008:administration & dosage / Q000009:adverse effects*; D014363:Tryptamines; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000009:adverse effects*
D007211:Indoles; D010880:Piperidines; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; D014662:Vasoconstrictor Agents; D018170:Sumatriptan; C106783:naratriptan